Playback speed
10 seconds
Will Immunotherapy Shift Treatment Balance for Borderline Resectable Stage III NSCLC?
By
Beacon Medical Interchange
FEATURING
Jack West
By
Beacon Medical Interchange
FEATURING
Jack West
254 views
November 2, 2018
Dr. Jack West reviews the implications of the PACIFIC trial that establishes a role for ...
read more ↘ durvalumab immunotherapy in stage III NSCLC, and which will likely lead to some patients shifting away from surgery in favor of chemoradiation followed by durvalumab.
↖ read less
read more ↘ durvalumab immunotherapy in stage III NSCLC, and which will likely lead to some patients shifting away from surgery in favor of chemoradiation followed by durvalumab.
↖ read less
Comments 0
Login to view comments.
Click here to Login
Lung